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Background: Uridine (Urd), which has been reported as a major component of RNA, plays an important role in
various biological process including neuroprotection, biochemical modulation and glycolysis, although its role in
constipation has yet to be established. Therefore, in this study, we investigated the laxative effects of Urd on
chronic constipation.
Methods: The constipation phenotypes and their related mechanisms were investigated in the transverse colons
of SD rats with loperamide (Lop)-induced constipation after treatment with 100 mg/kg of Urd.
Results: The number, weight and water contents of stools were significantly higher in the Lop + Urd treated
group than the Lop + Vehicle treated group, while food intake and water consumption of the same group were
maintained at a constant level. The thickness of the mucosa layer, muscle and flat luminal surface, as well as the
number of goblet cells, paneth cells and lipid droplets were enhanced in the Lop + Urd treated group. Furthermore,
the expression of the muscarinic acetylcholine receptors M2 and M3 (mAChR M2 and M3) at the transcriptional
and translational level was recovered in the Lop + Urd treated group, while some markers such as Gα and inositol
triphosphate (IP3) in their downstream signaling pathway were completely recovered by Urd treatment. Moreover,
the ability for mucin secretion and the expression of membrane water channel (aquaporine 8, AQP8) were
increased significantly in the Lop + Urd treated group compared with Lop + Vehicle treated group. Finally, the
activity of Urd was confirmed in primary smooth muscle of rat intestine cells (pRISMC) based on Gα expression and
IP3 concentration.
Conclusions: The results of the present study provide the first strong evidence that Urd can be considered an
important candidate for improving chronic constipation induced by Lop treatment in animal models.
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Constipation is an acute or chronic gastrointestinal
disease characterized by infrequent bowel movements,
hard and dry feces, incomplete bowel evacuation and
difficulty during defecation [1]. Although a variety of
treatments for this disease are known, the best method* Correspondence: dyhwang@pusan.ac.kr
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to incorporate more fiber into the diet, drink plenty of
fluids, and add exercise into the patient’s daily routine.
In most cases, chemical drugs (laxatives) such as senna,
correctol, exlax, senokot and gaviscon can be widely pre-
scribed to help patients pass stools [2]. These drugs act
as stimulants to increase bulkiness and soften stool, or
as osmotic agents, enhancing water flow into the colon
to promote elimination and trigger bowel movements.
However, most of these agents have undesirable side
effects including artery contraction, coronary spasmsle is distributed under the terms of the Creative Commons Attribution 4.0
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tion of novel laxatives with no side effects has been the
main focus of the constipation treatments.
Urd, which is one of the five standard nucleosides that
makes up nucleic acids, is a glycosylated pyrimidine-
analog consisting of uracil linked to a ribose ring [6].
After phosphorylation to nucleotides, Urd was used for
the synthesis of nucleic acid and membrane constitu-
ents, as well as glycosylation [7]. Moreover, Urd is widely
involved in a variety of biochemical processes including
the glycolysis pathway, biochemical modulation and
neuroprotection. Urd plays a role in the glycolysis
pathway of galactose even if catabolic processes for the
metabolism of galactose are not involved this process
[8]. Furthermore, Urd has been used successfully as a
biochemical modulating agent to alleviate the side effects
of various anti-cancer and anti-HIV drugs, although
fever and diarrhea have been considered the major
factors limiting increasing the dose of Urd [9–11].
Urd is the major form of pyrimidine nucleoside
taken up by the brain, and it has been suggested
that it be used as a neuroprotective agent to treat
epileptic and neurodegenerative diseases, including
depression and Alzheimer’s disease [7, 12]. Urd acts
as a central nervous system (CNS) depressant, hav-
ing anticonvulsant effects and inducing decreased
spontaneous activity of adult male C-57 mice [13,
14] Although studies conducted to date have pro-
vided some information regarding the possibility of a
correlation between intestinal bowel disease and Urd,
no studies have investigated the laxative effects of
Urd in the constipated animal model.
Therefore, the present study was conducted to ver-
ify the laxative activity and action mechanism of Urd
in a Lop-induced constipation model. Our results
provide the first scientific evidence that Urd can suc-
cessfully induce laxative effects in the constipated ani-
mal model without any significant side effects.
Methods
Experimental design for animal study
Adult SD rats purchased from Samtako Inc. (Osan,
Korea) were handled in the Pusan National University-
Laboratory Animal Resources Center, which is accre-
dited by the Korea Food and Drug Administration
(FDA)(Accredited Unit Number-000231) and AAALAC
International according to the National Institutes of
Health guidelines (Accredited Unit Number; 001525).
Animals were provided with ad libitum access to a
standard irradiated chow diet (Samtako Inc.) and water.
During the experiment, rats were maintained in a spe-
cific pathogen-free (SPF) state under a strict light cycle
(lights on at 08:00 h and off at 20:00 h) at 23 ± 2 °C and
50 ± 10% relative humidity.Constipation of SD rats was induced by subcutane-
ously injection of Lop as previously described [5, 15].
First, 8-week-old SD rats (n = 28) were assigned to either
a non-constipation group (No group, n = 14) or a consti-
pation group (n = 14). Constipation was induced by sub-
cutaneous injection of Lop (4 mg/kg weight) in 0.5%
Tween 20 in saline twice a day for 3 days, whereas the
non-constipation group was injected with 0.5% Tween
20 in saline alone. The non-constipation group was
further divided into a No treated group (n = 7) and a
Urd treated group (n = 7). The No treated group was un-
treated during the experimental period, whereas the Urd
treated group received 100 mg/kg Urd (Sigma-Aldrich
Co., Saint Louis, MO, USA) at one time. Additionally,
the constipation group was further divided into a Lop +
Vehicle treated group (n = 7) and Lop + Urd treated
group (n = 7). The Lop + Urd treated groups were orally
administered 100 mg/kg body weight Urd at once, while
the Lop + Vehicle treated group received the same vol-
ume of 1× PBS under the same pattern. At 24 h after
Urd treatment, all SD rats were euthanized using CO2
gas and tissue samples were acquired and stored in
Eppendorf tubes at −70 °C until assay.
Analysis of food intake, water intake and body weight
Alterations in food intake, water consumption and
body weight of SD rats treated with Lop + Urd were
measured daily at 10:00 am throughout the experi-
mental period using an electrical balance and a meas-
uring cylinder. All measurements were performed
three times to ensure accuracy.
Measurement of stool parameters
During all experimental periods, SD rats of all groups
were bred in metabolic cages to harvest pure stools and
urine without any contamination (Daejong Instrument
Industry Co., LTD, Seoul, Korea). The stool number and
weight were measured as previously described [15, 16].
The stools excreted from each SD rat were collected at
10:00 am. Stool samples were weighed three times per
sample using an electric balance, whereas the number of
stools was counted three times.
Western blotting
Total proteins were extracted from the transverse colons
of subset groups (No, Urd, Lop + Vehicle and Lop + Urd
treated SD rats) and pRISMCs using Pro-Prep Protein
Extraction Solution (Intron Biotechnology, Inc., Seong-
nam, Korea). Following centrifugation at 13,000 rpm and
4 °C for 5 min, the protein concentrations were deter-
mined using a SMARTTM Bicinchoninic Acid Protein
assay kit (Thermo Fisher Scientific, Inc.). Proteins (30 μg)
were separated by 4–20% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) for 3 h,
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nitrocellulose membranes for 2 h at 40 V. Each membrane
was then incubated separately with primary antibody, anti-
mAChR M2 antibody (Alomone Labs, Jerusalem, Israel),
anti-PI-3K (Cell Signaling Technology Inc., Cambridge,
MA, USA), anti-p-PI3K (Cell Signaling Technology Inc.),
anti-mAChR M3 antibody (Alomone Labs, Jerusalem,
Israel), anti-PKC (Cell Signaling Technology Inc.), anti-
p-PKC (Cell Signaling Technology Inc.), anti-Gα (Abcame,
Cambridge, UK) or anti-actin (Sigma-Aldrich Co.) over-
night at 4 °C. Next, the membranes were washed with
washing buffer (137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 2 mM KH2PO4, and 0.05% Tween 20) and
incubated with horseradish peroxidase-conjugated goat
anti-rabbit IgG (Zymed Laboratories, South San Francisco,
CA, USA) at a dilution of 1:1000 and room temperature for
2 h. Finally, the membrane blots were developed using
Chemiluminescence Reagent Plus kits (Pfizer, New York,
NY, USA and Pharmacia, New York, NY, USA).
RT-PCR
Total RNA was isolated from the frozen tissue of trans-
verse colons using RNAzol B solution (Tet-Test Inc.) ac-
cording to manufacturer’s protocols. After the synthesis
of cDNA, genes were amplified by subjecting the sam-
ples to 28 cycles of 30 s at 94 °C, 30 s at 62 °C and 45 s
at 72 °C in a Perkin-Elmer Thermal Cycler. The primer
sequences used to evaluate mAChR M2 expression were
as follows: sense primer, 5′-CCAGT ATCTC CAAGT
CTGGT GCAAG G-3′, antisense primer, 5′-GTTCT
TGTAA CACAT GAGGA GGTGC-3′. The primer se-
quences used to evaluate mAChR M3 expression were
as follows: sense primer, 5′-GTCAC TTCTG GTTCA
CCACC AAGAG C-3′, antisense primer, 5′-GTGTT
CACCA GGACC ATGAT GTTGT AGG-3′. The primer
sequences used to evaluate AQP8 expression were as fol-
lows: sense primer, 5′-GTAGT ATGGA CCTAC GTGAG
ATCAA GG-3′, antisense primer, 5′-AGAAC CTTTC
CTCTG GACTC ACCAC C-3′. The primer sequences
used to evaluate MUC2 expression were as follows: sense
primer, 5′-GCTGC TCATT GAGAA GAACG ATGC-3′,
antisense primer, 5′-CTCTC CAGGT ACACC ATGTT
ACCAG G-3′. The sequences of the β-actin sense and
antisense primers were 5′-TGGAA TCCTG TGGCA
TCCAT GAAAC-3′ and 5′-TAAAA CGCAG CTCAG
TAACA GTCCG-3′, respectively. The PCR products were
quantified using 1% agarose gels and a Kodak Electrophor-
esis Documentation and Analysis System 120.
Histopathological analysis
Transverse colons collected from No, Urd, Lop + Vehicle
and Lop + Urd treated SD rats were fixed with 10%
formalin for 48 h, embedded in paraffin wax, and then
sectioned into 5 μm thick slices that were stained withhematoxylin and eosin (H&E, Sigma-Aldrich Co.). Mor-
phological features of these sections were observed by
light microscopy, after which the mucosa thickness,
muscle thickness, flat luminal surface thickness, number
of goblet cells and number of lipid droplets were mea-
sured using Leica Application Suite (Leica Microsystems,
Switzerland).
For mucin staining, transverse colons collected
from SD rats that had been cotreated with Lop +
Urd were fixed with 10% formalin for 48 h, embed-
ded in paraffin wax, and then sectioned into 4 μm
thick slices that were subsequently deparaffinized
with xylene and rehydrated. Next, the tissue sections
on the slides were rinsed with distilled water and
stained with an Alcian Blue Stain kit (IHC WORLD,
Woodstock, MD, USA). Finally, the morphological
features in the stained colon sections were observed
by light microscopy.
Ultrastructure analysis using transmission electron
microscopy (TEM)
The transverse colons collected from SD rats of subset
groups were fixed in 2.5% glutaraldehyde in 1× PBS buf-
fer, washed, dehydrated with ascending concentrations
of ethanol, incubated in 1% OsO4 for 1 h at room
temperature, and then embedded in Epon812 media
(Polysciences Inc., Eppelheim, Germany). Ultra-thin sec-
tions (70 nm) were subsequently collected on holey for-
mvar coated grids, contrasted with uranyl acetate and
lead citrate, and examined by TEM (Hitachi, Tokyo,
Japan) at 4000× magnification.
Measurement of IP3 concentration
The levels of IP3 were determined using an IP3 ELISA
kit (Cusabio Biotech Co., Ltd., Wuhan, China) according
to the manufacturer’s instructions. Briefly, the pRISMCs
(5 × 107) were washed and homogenized in ice-cold PBS
(pH 7.2–7.4) with a glass homogenizer (Sigma-Aldrich
Co.). The cell lysates were then centrifuged at 1000 rpm
for 5 min at room temperature, after which the super-
natant was collected for analysis. An anti-IP3 detection
antibody was added and incubated at 37 °C for 60 min,
after which substrate solution was added and the sam-
ples were incubated for 15 min at 37 °C. The reaction
was terminated following the addition of stop solution
and the plates were read at an absorbance of 450 nm
using a Molecular Devices VERSA max Plate reader
(Molecular Devices, Sunnyvale, CA, USA).
Treatment and preparation of pRISMC
pRISMCs used in this study were prepared from intes-
tines of infant rats (3 days old)(n = 3) as previously
described, with some modification [17]. Moreover, the
purity of the pRISMCs population was confirmed by RT-
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scribed [18]. Amplification was conducted in a Perkin-
Elmer Thermal Cycler using the following cycles: 30 s at
94 °C, 30 s at 62 °C, and 45 s at 72 °C. The primer se-
quences for target gene expression identification were as
follows: Myh11 (myosin-smooth muscle cells marker),
sense primer: 5′-GCAAC TGAGC AATGA GCTGG
TCAC-3′, anti-sense primer: 5′-CTGCT CCTTG TACTG
CTCCA CCATC-3′; PGP9.5 (neuronal cell marker), sense
primer: 5′-TACTT CATGA AGCAG ACCAT CG-3′, anti-
sense primer: 5′-CTGCA GCAGA GAGTC CTCTG
AACTG-3′; β-actin, sense primers; 5′-TGG AAT CCT
GTG GCA TCC ATG AAA C-3′, anti-sense primer: 5′-
TAA AAC GCA GCT CAG TAA CAG TCC G-3′. The
final PCR products were separated on 1.2% agarose gel and
then visualized by ethidium bromide staining. Among the
two markers, only Myh11, indicating myosin-smooth
muscle cells, was detected at high levels, while PGP9.5,
indicating neuronal cells, was found at an extremely low
level (Fig. 6a).
To treat Urd, pRISMCs were seeded at a density of
1 × 107 cells/10 ml in 100 mm-diameter culture dishes,
then grown with 20 μM Lop in a 37 °C incubator. After
12 h, cells were removed from the culture media with
Lop and incubated with 100 μM Urd or 1× PBS for an-
other 12 h. Next, cells harvested from 100 mm diameter
culture dishes were used to determine the IP3 concen-
tration and for western blot analysis.
Statistical analysis
One-way ANOVA (SPSS for Windows, Release 10.10,
Standard Version, Chicago, IL, USA) was used to de-
termine the variance and identify significant differences
between the No treated group and others groups, as
well as between the Vehicle treated group and Urd
treated group within the constipation group. All values
are presented as the means ± standard deviation (SD).
A p <0.05 was considered significant.Table 1 Measurement of body weight, feeding behavior, stools and
Contents No
Body weight (g) 270 ± 11.1
Feeding behavior
Food intake (g/day) 18.3 ± 2.2
Water consumption (ml/day) 14.3 ± 2.1
Stool
Stool number (ea) 64.7 ± 9.5
Stool weight (g) 8.8 ± 1.0
Water content (%) 35.3 ± 3.1
Urine volume (ml/day) 13 ± 1.6
Data represent the means ± SD from three replicates. *p < 0.05 compared to the No
Urd; uridine, Lop; loperamideResults
Effect of Urd administration on feeding behavior and
excretion parameters
To investigate whether Urd administration could affect
the feeding behavior and excretion parameters of consti-
pated rats, alterations in food intake, water consump-
tion, stool number, and weight and water contents of
stools were measured in Lop-induced constipated SD
rats after Urd administration. As shown Table 1, no sig-
nificant alterations in body weight, food intake or water
consumption were observed. However, the decreases in
the number, weight and water contents of stools in the
Lop + Vehicle treated group were almost recovered in
the Lop + Urd treated groups relative to those in the No
and Urd treated group, although there were a few differ-
ences in the recovery rate. The opposite pattern was ob-
served for the urine volume (Table 1).
Effect of Urd administration on histological structure of
the transverse colon
We investigated whether Urd treatment could induce al-
terations in the histological structure of the transverse
colon. To accomplish this, alterations in the histological
parameters indicating laxative effects were measured in
the H&E stained transverse colons of subset groups. The
Urd treated group showed a similar structure as the No
treated group. A significant decrease in the thickness of
mucosa, muscle and flat luminal surface was observed in
the Lop + Vehicle treated group relative to the No
treated group and the Urd treated group. However, these
levels dramatically increased by 283, 219 and 39%
following Lop + Urd cotreatment when compared with
the Lop + Vehicle treated group (Fig. 1 and Table 2).
Furthermore, the number of goblet cells, crypt of lieber-
kuhn and enterocytes were 41, 54 and 34% lower in the
Lop + vehicle treated group than the No treated group,
respectively (Table 2). However, these levels were recov-
ered in the Lop + Urd treated groups, although noturine secretion in Lop-induced constipated SD rats
Urd Lop
Vehicle Urd
267 ± 14.5 261 ± 18.7 254 ± 17.4
18.4 ± 1.5 16.4 ± 1.9 16.1 ± 2.0
15.7 ± 2.1 13.3 ± 4.1 15.7 ± 1.9
65.7 ± 9.7 38.0 ± 13.1* 67.5 ± 12.2#
9.0 ± 1.5 5.2 ± 2.2* 10.0 ± 2.2#
35.9 ± 3.2 14.6 ± 0.8* 30.8 ± 3.4#
13.3 ± 1.2 20.7 ± 1.7* 15.3 ± 1.7#
treated group. #p < 0.05 compared to the Lop + Vehicle treated group.
Fig. 1 Alteration of histological structures in Lop-induced constipated rats. H&E stained sections of transverse colon rats from the No, Urd,
Lop + Vehicle or Lop + Urd treated group were observed at 100× (left column) and 200× (right column) using a light microscope. Five to
six rats per group were assayed in triplicate by H&E
Table 2 Histopathological alterations in constipated SD rats after Urd treatment
Contents No Urd Lop
Vehicle Urd
Mucosa layer thickness (μm) 394 ± 35.2 415 ± 21.3 105 ± 12.5* 402 ± 23.5#
Muscle thickness (μm) 89.3 ± 6.5 92.3 ± 7.6 28.3 ± 4.3* 90.2 ± 6.6#
Flat luminal surface thickness (μm) 16.1 ± 3.2 15.4 ± 2.3 10.6 ± 1.1* 14.8 ± 2.0#
Number of goblet cells (ea) 85.6 ± 8.5 88.4 ± 6.7 51.2 ± 5.5* 72.6 ± 9.8#
Number of crypt of lieberkuhn (ea) 12.5 ± 2.6 14.2 ± 1.5 5.8 ± 1.1* 11.2 ± 2.1#
Number of enterocytes (ea) 125.2 ± 8.6 117.8 ± 7.7 82.3 ± 9.2* 102.4 ± 7.8#
*p < 0.05 compared with the non-constipation group. #p < 0.05 compared with the Lop + Vehicle treated constipation group. Urd; uridine, Lop; loperamide
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Table 2).
Effect of Urd administration on ultrastructure of the
transverse colon
Based on the above histopathological alterations, we ex-
amined whether Urd administration could accompany
alterations in the ultrastructure of the transverse colon.
To accomplish this, ultrastructural changes were observed
in thin tissue section of the transverse colon using TEM
analysis. In the No treated group and the Urd treated
group, the Crypt of Lieberkuhn was clearly observed as a
ring structure in which enterocytes, goblet cells, and
paneth cells surrounded a lumen at the center. Following
Lop treatment, the ultrastructure of the crypt changed
dramatically. The number of paneth cells and lipid drop-
lets was also higher in the Lop + Vehicle treated group
than in the No-treated group. However, their levels were
significantly recovered or they disappeared from aroundFig. 2 Ultrastructure image of transverse colon. a The ultrastructure of the
viewed by TEM at 4000× magnification. b The number of paneth cells, lipid
Suite (Leica Microsystems, Switzerland). Five to six rats per group were assa
distributed around the lumen of the crypt. Data represent the mean ± SD f
#, p < 0.05 compared to the Lop + Vehicle treated group. Lm, lumen of crypthe cryp lumen in the Lop +Urd treated group. The de-
crease in the average size and number of goblet cells in
the Lop + Vehicle treated group was also enhanced in the
Lop +Urd treated group (Fig. 2).
Correlation between the laxative effects of Urd and
downstream signaling pathway of mAchRs
We next investigated the molecular mechanism of the
laxative effects of Urd in the constipation model. To
accomplish this, the mRNA and protein of mAChRs M2
and M3 were measured in the transverse colon of the
Lop + Urd treated group using specific primers and
antibodies. A similar alteration pattern in the mRNA
and proteins of mAChRs M2 and M3 was observed in
the subset group. The levels of these two receptors were
lower in the Lop + Vehicle treated group than the No
treated group and the Urd treated group. However, their
levels rapidly increased by 303 and 395% in the Lop +
Urd treated group (Fig. 3).crypt in the No, Urd-, Lop + Vehicle and Lop + Urd treated group was
droplets and goblet cells was measured using Leica Application
yed in triplicate by TEM analysis. The arrow indicates a lipid droplet
rom three replicates. *, p < 0.05 compared to the No treated group.
t; Gb, goblet cells; Pn, paneth cells
Fig. 3 Expression of mAChRs transcript and protein in the transverse colon. a The expression of mAChR M2 and M3 proteins was measured by
Western blot analysis using HRP-labeled anti-rabbit IgG antibody. b The levels of mAChR M2 and M3 transcripts in the total mRNA of transverse
colons were measured by RT-PCR using specific primers. After the intensity of each band was determined using an imaging densitometer, the
relative levels of mAChR M2 and M3 were calculated based on the intensity of actin. Five to six rats per group were assayed in triplicate by western
blot and RT-PCR assays. Data represent the means ± SD of three replicates. *, p < 0.05 compared to the No treated group. #, p < 0.05 compared to the
Lop + Vehicle treated group
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of mAChR were also observed. The overall change in all
experimental groups was very similar to the changes in
the expression of PKC, p-PKC, PI3K and p-PI3K
proteins. Specifically, these levels were dramatically
increased by 2900 and 300%, respectively, in the Lop +
Vehicle treated group relative to the No and Urd treated
group. However, their levels significantly recovered inLop + Urd treated groups, even though the rate of
decrease varied (Fig. 4).
Effect of Urd administration on regulation of the ability to
secrete mucin
To determine if Urd treatment could enhance the ability
to secrete mucin in the transverse colon, the levels of
mucin were observed in tissue sections of the transverse
Fig. 4 Expression of key proteins in the mAChR M2 and M3 downstream signaling pathway. The expression of several related proteins including
PKC, p-PKC, PI3K and p-PI3K was measured by Western blot analysis using HRP-labeled anti-rabbit IgG antibody. After the intensity of each band
was determined using an imaging densitometer, the relative levels of four proteins were calculated based on the intensity of actin protein. Five
to six rats per group were assayed in triplicate by Western blotting. Data represent the means ± SD of three replicates. *, p < 0.05 compared to
the No treated group. #, p < 0.05 compared to the Lop + Vehicle treated group
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and the Urd treated group, the region stained with dark
blue indicating mucin was concentrated into the crypt in
the mucosa layer of the transverse colon. The level of
mucin was decreased in the Lop + Vehicle treated group
and dramatically increased in the Lop + Urd treated
group (Fig. 5a). A similar pattern was also detected in
the expression level of MUC2 mRNA. The decrease in
the level of this gene in the Lop + Vehicle treated group
was significantly increased by 165% in the Lop + Urd
treated group. Furthermore, we investigated whether
mucin secretion induced by Urd treatment was accom-
panied by altered expression of a membrane water
channel by measuring the level of AQP8 mRNA in the
transverse colon of subset groups. The level of AQP8
mRNA was very similar to that of MUC2 mRNA. These
values decreased by 90.5% in the Lop + Vehicle relative
to the No treated group, but AQP8 mRNA wasdramatically increased in the Lop + Urd treated groups
(Fig. 5b).
Confirmation of Urd effects in pRISMC
Finally, we confirmed the laxative effect of Urd in
pRISMCs collected from the transverse colon. The
expression of Gα protein was 42% higher in the Lop +
Vehicle treated group than the No treated group.
However, these levels were dramatically decreased after
Lop + Urd treatment (Fig. 6b). Additionally, significant
alterations were observed upon analysis of the IP3
concentration. The decrease in IP3 in the Lop + Vehicle
treated group was significantly recovered after Lop +
Urd treatment (Fig. 6c).
Discussion
Herbal plants and natural products have recently re-
ceived increased attention as novel therapeutic drugs for
Fig. 5 Detection of mucin secretion and membrane water channel expression. a Mucin secreted from crypt layer cells was stained with alcian
blue at pH 2.5 and their images were observed at 100× magnification. The high magnification image (200×) is presented in the right corner of
each figure. Five to six rats per group were assayed in triplicate by alcian blue staining. b The levels of MUC2 and AQP8 transcripts in the total
mRNA of transverse colons were measured by RT-PCR using specific primers. After the intensity of each band was determined using an imaging
densitometer, the relative levels of MUC2 and AQP8 mRNA were calculated based on the intensity of actin as an endogenous control. Five to six
rats per group were assayed in triplicate by RT-PCR assays. Data represent the means ± SD of three replicates. *, p < 0.05 compared to the No
treated group. #, p < 0.05 compared to the Lop + Vehicle treated group
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cause they show a significant possibility for the preven-
tion and treatment of inflammation related diseases [16,
19, 20]. Some studies have been focused on the identifi-
cation of key compounds involved in constipation al-
though they did not report key compounds with laxative
effects. In an effort to identify drugs for the treatment of
constipation, we investigated the therapeutic effects of
Urd on Lop-induced constipated SD rats because Urd
have been detected from extracts of several medicinal
plants that have therapeutic effects against some humandiseases. These included the aqueous extract of Isatis
indigotica, which has anti-cancer and anti-viral effects
[21, 22], and the extract of Longan arillus, which has
anxiolytic-like effects [23]. In addition, Urd was detected
in the alkaloid extract of Pinelliae pedatisecta, which has
anti-cancer effects [24]. The results of the present study
clearly demonstrated that Urd may induce laxative ef-
fects, including elevation of stool excretion and the re-
covery of histological changes induced by Lop injection
in the transverse colon. Our data are the first to demon-
strate that the laxative effects of Urd are tightly
Fig. 6 Detection of Gα expression and IP3 concentration in pRISMC. a pRISMCs were collected from the small intestines of infant rats and
confirmed by RT-PCR analysis using specific primers. b Total cell lysate protein was extracted from Lop-pretreated pRISMC after treatment with
the Urd. The levels of Gα expression were detected using specific antibodies. The actin level is also shown as an endogenous control. The band
intensity of the three proteins was determined using an imaging densitometer and the relative level of each protein was calculated based on the
intensity of actin protein as an endogenous control. b After treatment with Lop for 12 h, pRISMC were further incubated with Urd as described in
the materials and methods. The IP3 concentration in the total cell lysate was measured using an ELISA kit that could detect IP3 at 5 pg/ml to
1000 pg/ml. Data represent the means ± SD of three replicates. *, p < 0.05 compared to the No treated group. #, p < 0.05 compared to the Lop +
Vehicle treated group
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ing pathway, up-regulation of the mucin secretion ability
and water content capacity in the transverse colon.
Neurobiological roles of Urd have been investigated in
many pharmacological studies, but none of these have
provided direct evidence of a relationship between Urd
and intestinal function [6]. Urd can bypass the bloodbrain barrier by binding one of two transporters, high af-
finity transporter (1–50 μM range) and low affinity
transporter (100–800 μM range) [25, 26]. Urd also medi-
ates as a novel neurotransmitter via purinergic receptor
(P2 receptor) in response to extracellular purine and py-
rimidines when it is not providing a substrate for phos-
phatidylcholine synthesis [27, 28]. It can also induce the
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through enhancement of phosphatidylcholine levels in
the brain as well as neuronal differentiation and out-
growth via activation of NGF signaling [29, 30]. Further-
more, administration of some drugs containing uridine
and uridine-5-monophosphate enhanced dopamine out-
put from activated neurons by 11.6–20.5% and improved
spatial short term memory, recognition, recall, attention
and executive function [30]. Although the above studies
suggested that Urd can be potentially used as laxative
compounds, there are however, no direct scientific evi-
dence on the therapeutic effect of Urd for chronic con-
stipation. Therefore, the results of the present study
provide the first evidence that the laxative effects of Urd
may correlate with neuronal functions of the transverse
colon. However, more studies are needed to elucidate
the molecular mechanism responsible for the effects of
Urd against chronic constipation.
Alterations in excretion factors such as number,
weight and water contents of stools in Lop-injected rats
were dramatically recovered by treatment with herbal
medicines such as Aloe ferox Mill., Liriope platyphylla
and Mareya micrantha Mull. [5, 15, 20]. However, the
rate of increase varied in each group treated with differ-
ent herbal medicine. The stool weight was enhanced by
176–272% in rats treated with the aqueous extract of
Mareya micrantha, while it was increased by 71–143%
in the case of Aloe ferox Mill. treatment [15, 20]. More-
over, an increase of 52–80% and 86% in the number of
stools was measured in the group treated with the
aqueous-methanol extract of Fumaria parviflora and
aqueous extract of L. platyphylla (AEtLP) [5, 31]. In our
study, the number, weight and water content of stools
increased by 77.6, 92.3 and 110.9%, respectively, in the
Lop + Urd treated group when compared with the Lop +
Vehicle treated group. These findings were similar to
those observed for in animals treated with several herbal
medicines, although the level of each parameter ex-
tended in broad range.
Stool excretion, histopathological structure of colon,
mucin secretion and mAChR expression are considered
to be important factors for evaluation of constipation
symptoms and therapeutic effects of some drugs [5, 15,
16, 32]. However, in the most studies conducted to date,
the laxative effects were measured using stool excretion
parameters, including number, weight, and water con-
tent, as well as histopathological features of the colon
including thickness of the villus layer, crypt layer and
muscle layer after the administration of various plant
extracts [15, 20]. In this study, similar results were
detected in the above parameters, although the alter-
ation rate varied in each group. Therefore, these results
indicate that Urd administration could improve Lop-
induced constipation through stimulation of stool andurine excretion, recovery of the histopathological struc-
ture, and mucin secretion. OUr study also investigated
the molecular mechanism responsible for the mAChR
signaling pathway and mucin secretion in constipated
SD rats treated with Urd. The results regarding the ef-
fects of Urd on the mAChR signaling pathway and
mucin secretion provide basic information that will be
useful to future studies of the causes of constipation and
selection of targets for constipation treatment.
IP3 can also be considered one of the factors related to
bowel movements because it induces increases in intracel-
lular Ca2+ levels through a release from the sarcoplasmic
reticulum [33]. Smooth muscle tone in the intestine is
controlled by phosphorylation of the regulatory light chain
(MLC) of myosin II. Ca2+/CaM-dependent myosin light
chain kinase and myosin phosphatase regulated this
process to control the velocity and force of actomyosin
cross-bridging [34]. Therefore, we measured the IP3 level
in pRISMC to investigate the effects of Urd response to
Lop treatment. The results of the present study suggest
that Urd may play an important role in pRISMCs col-
lected from the small intestine of infant rats treated with
Lop and that its effects are tightly correlated with those of
laxatives that improve chronic constipation.
AQP, which is one of the membrane water channels
that control water content in various cells, is connected
to several diseases including congenital cataracts and
nephrogenic diabetes insipidus [35]. Among several sub-
types of AQPs distributed in the intestinal epithelial
cells, AQP8 is primarily expressed in the absorptive
epithelial cells and localized normally in colonic epithe-
lial cells [36, 37]. The expression of AQP8 was observed
as three major patterns based on their pathological
condition. In most cases, the expression of this gene is
downregulated in experimental colitis [38], inflammatory
bowel diseases [38], diarrhea-predominant bowel syn-
drome (D-IBD) [39], melanosis coli [40], rotavirus-
induced diarrhea [41] and ulcerative colitis [42]. How-
ever, AQP8 mRNA and protein levels were significantly
enhanced in the colon of ulcerative colitis [43] and para-
neoplastic normal tissues [44]. Furthermore, AQP8 was
not expressed in the colonic mucosa of slow transit
constipation rats treated with diphenoxylate solution
[45]. In the present study, the level of AQP8 mRNA was
significantly decreased in the Lop + Vehicle treated
group when compared with the No treated group. This
pattern was very similar to that of several bowel diseases,
although the decrease rate varied. However, the level of
AQP8 in the Lop treated group differed from that of the
constipation induced by diphenoxylate solution. It is
likely that the observed differences between studies can
be attributed to the disease induction mechanism of the
compound; however, more studies are needed to under-
stand what other factors determine AQP8 expression.
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chronic constipation, including the extension of stool
evacuation time and the delay of intestinal luminal tran-
sit SD rats and ICR mice through inhibition of water se-
cretion [46] and smooth movement in the intestinal wall
[47, 48]. However, this animal model induced by Lop in-
jection could only simulate slow transit constipation
among three afflictions categorized in human patients
based on assessment of colonic transit and anorectal
function; normal transit or irritable bowel syndrome,
pelvic floor dysfunction (functional defecatory disorders)
and slow transit constipation [49–51]. Therefore, the
present study has some limits and restrictions to the
clinical translation of results obtained from Lop induced
rats to human conditions.
Alterations in endogenous metabolites were also ex-
amined in the serum of Lop-induced constipation rats.
Among 35 endogenous metabolites, four amino acids
(alanine, glutamate, glutamine and glycine) and six en-
dogenous metabolites related to the glycolysis pathway
(acetate, glucose, glycerol, lactate, succinate and taurine)
were dramatically decreased after Lop treatment [52].
These results provide a possibility that Urd can rescue
the Lop-induced constipation by interfering with the bal-
ance of metabolites because Urd plays a role in the gly-
colysis pathway of galactose [53]. However, additional
studies are needed to determine if this is the case.Conclusions
The results of the present study provide the first strong
evidence that Urd could induce the recovery of patho-
logical symptoms including excretion parameters, histo-
logical structure, ultrastructure mucin secretion and
water homeostasis in Lop-induced constipation SD rats.
Our results also provide information that will help eluci-
date the laxative mechanism of Urd on the downstream
signaling pathway and expression of mAChRs.Abbreviations
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